The North America Advanced Therapy Medicinal Products CDMO Market would witness market growth of 15.7% CAGR during the forecast period (2022-2028).
Medications based on somatic cell therapy contain tissues or cells that have been modified in order to alter their biological properties. Alternatively, these medicines contain tissues or cells that are not meant to be employed for the same vital tasks in the body. They have applications in the treatment, diagnosis, and prevention of several diseases.
Tissue-engineered medicines contain tissues or cells that have been manipulated so that they can be utilized to repair, replace, or regenerate human tissue. Additionally, certain ATMPs may incorporate medical devices as an indispensable aspect of the medicine. Products derived from cell therapy, tissue engineering, and gene therapy belong to the domain of biological goods intended for use on humans.
The market is developing as a result of increasing conviction and awareness among researchers regarding the benefits of advanced therapy as well as increased clinical research of ATMP. Because of the growing need for innovative treatments, the market is undergoing transformation. The increase can be ascribed to the emergence of fatal and rare diseases, like ophthalmic and metabolic illnesses, as well as increased financing for the R&D of advanced therapeutic medicinal products.
Canada invests heavily in biopharmaceutical research and development, and as a result, it has grown to be a significant producer of vaccines. Additionally, the presence of significant domestic and foreign companies that produce vaccines is also propelling the growth of biopharmaceutical industry in the nation. According to estimates, the development of the regional industry will be supported by the developed countries like the US and Canada's robust healthcare systems. Additionally, during the course of the forecast period, the advanced therapy medicinal products CDMO market would expand more quickly due to the rising popularity of stem cell and regenerative medicine treatments.
The US market dominated the North America Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4,081.5 million by 2028. The Canada market is poised to grow at a CAGR of 18.3% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 17.3% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
Medications based on somatic cell therapy contain tissues or cells that have been modified in order to alter their biological properties. Alternatively, these medicines contain tissues or cells that are not meant to be employed for the same vital tasks in the body. They have applications in the treatment, diagnosis, and prevention of several diseases.
Tissue-engineered medicines contain tissues or cells that have been manipulated so that they can be utilized to repair, replace, or regenerate human tissue. Additionally, certain ATMPs may incorporate medical devices as an indispensable aspect of the medicine. Products derived from cell therapy, tissue engineering, and gene therapy belong to the domain of biological goods intended for use on humans.
The market is developing as a result of increasing conviction and awareness among researchers regarding the benefits of advanced therapy as well as increased clinical research of ATMP. Because of the growing need for innovative treatments, the market is undergoing transformation. The increase can be ascribed to the emergence of fatal and rare diseases, like ophthalmic and metabolic illnesses, as well as increased financing for the R&D of advanced therapeutic medicinal products.
Canada invests heavily in biopharmaceutical research and development, and as a result, it has grown to be a significant producer of vaccines. Additionally, the presence of significant domestic and foreign companies that produce vaccines is also propelling the growth of biopharmaceutical industry in the nation. According to estimates, the development of the regional industry will be supported by the developed countries like the US and Canada's robust healthcare systems. Additionally, during the course of the forecast period, the advanced therapy medicinal products CDMO market would expand more quickly due to the rising popularity of stem cell and regenerative medicine treatments.
The US market dominated the North America Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4,081.5 million by 2028. The Canada market is poised to grow at a CAGR of 18.3% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 17.3% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Oncology
- Cardiology
- Central Nervous System & Musculoskeletal
- Infectious Disease
- Dermatology
- Endocrine, Metabolic, Genetic
- Immunology & Inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Others
By Product
- Gene Therapy
- Cell Therapy
- Tissue Engineered & Others
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc. (Patheon, Inc.)
- AGC Biologics, Inc. (AGC, Inc.)
- Catalent, Inc
- Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
- WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
- Lonza Group AG
- Celonic AG (JRS PHARMA GmbH & Co. KG)
- Rentschler Biopharma SE
- Bio Elpida (Polyplus-transfection SA.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Advanced Therapy Medicinal Products CDMO Market, by Indication
1.4.2 North America Advanced Therapy Medicinal Products CDMO Market, by Product
1.4.3 North America Advanced Therapy Medicinal Products CDMO Market, by Phase
1.4.4 North America Advanced Therapy Medicinal Products CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2019, Jan - 2022, Aug) Leading Players
Chapter 4. North America Advanced Therapy Medicinal Products CDMO Market by Indication
4.1 North America Oncology Market by Country
4.2 North America Cardiology Market by Country
4.3 North America Central Nervous System & Musculoskeletal Market by Country
4.4 North America Infectious Disease Market by Country
4.5 North America Dermatology Market by Country
4.6 North America Endocrine, Metabolic, Genetic Market by Country
4.7 North America Immunology & Inflammation Market by Country
4.8 North America Ophthalmology Market by Country
4.9 North America Hematology Market by Country
4.1 North America Gastroenterology Market by Country
4.11 North America Others Market by Country
Chapter 5. North America Advanced Therapy Medicinal Products CDMO Market by Product
5.1 North America Gene Therapy Market by Country
5.2 North America Cell Therapy Market by Country
5.3 North America Tissue Engineered & Others Market by Country
Chapter 6. North America Advanced Therapy Medicinal Products CDMO Market by Phase
6.1 North America Phase I Market by Country
6.2 North America Phase II Market by Country
6.3 North America Phase III Market by Country
6.4 North America Phase IV Market by Country
Chapter 7. North America Advanced Therapy Medicinal Products CDMO Market by Country
7.1 US Advanced Therapy Medicinal Products CDMO Market
7.1.1 US Advanced Therapy Medicinal Products CDMO Market by Indication
7.1.2 US Advanced Therapy Medicinal Products CDMO Market by Product
7.1.3 US Advanced Therapy Medicinal Products CDMO Market by Phase
7.2 Canada Advanced Therapy Medicinal Products CDMO Market
7.2.1 Canada Advanced Therapy Medicinal Products CDMO Market by Indication
7.2.2 Canada Advanced Therapy Medicinal Products CDMO Market by Product
7.2.3 Canada Advanced Therapy Medicinal Products CDMO Market by Phase
7.3 Mexico Advanced Therapy Medicinal Products CDMO Market
7.3.1 Mexico Advanced Therapy Medicinal Products CDMO Market by Indication
7.3.2 Mexico Advanced Therapy Medicinal Products CDMO Market by Product
7.3.3 Mexico Advanced Therapy Medicinal Products CDMO Market by Phase
7.4 Rest of North America Advanced Therapy Medicinal Products CDMO Market
7.4.1 Rest of North America Advanced Therapy Medicinal Products CDMO Market by Indication
7.4.2 Rest of North America Advanced Therapy Medicinal Products CDMO Market by Product
7.4.3 Rest of North America Advanced Therapy Medicinal Products CDMO Market by Phase
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc. (Patheon, Inc.)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 AGC Biologics, Inc. (AGC, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.2.5.3 Geographical Expansions:
8.3 Catalent, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.4 Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental Analysis
8.5.4 Recent strategies and developments:
8.5.4.1 Product Launches and Product Expansions:
8.5.4.2 Acquisition and Mergers:
8.5.4.3 Partnerships, Collaborations, and Agreements:
8.6 Lonza Group AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Geographical Expansions:
8.7 Celonic AG (JRS PHARMA GmbH & Co. KG)
8.7.1 Company Overview
8.8 Bio Elpida (Polyplus-transfection SA.)
8.8.1 Company Overview
8.9 Rentschler Biopharma SE
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Partnerships, Collaborations, and Agreements:
8.9.2.2 Acquisition and Mergers:
Companies Mentioned
- Thermo Fisher Scientific, Inc. (Patheon, Inc.)
- AGC Biologics, Inc. (AGC, Inc.)
- Catalent, Inc.
- Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
- WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
- Lonza Group AG
- Celonic AG (JRS PHARMA GmbH & Co. KG)
- Rentschler Biopharma SE
- Bio Elpida (Polyplus-transfection SA.)
Methodology
LOADING...
